目的 采用网络药理学和分子对接方法，基于“药材–成分–靶标–通路”关联网络，揭示鸡骨草治疗乙型肝炎的作用机制。方法 采用中药系统药理学数据库及分析平台（TCMSP）筛选鸡骨草中OB≥30%且DL≤0.18的活性成分，补充文献报道中鸡骨草代表性成分，通过Swiss target prediction在线预测靶标，整合GeneCards、DisGeNET数据库中乙型肝炎靶标，利用Cytoscape筛选核心靶标并进行GO和KEGG富集分析，利用分子对接技术验证核心靶标和作用成分的结合模式。结果 鸡骨草中21个活性成分作用91个乙型肝炎靶标，包括17个核心靶标，包括ESR1、MMP9、STAT3、JUN等，核心成分包括相思子碱、相思子皂醇、大豆甾醇、2', 4'-二羟基查尔酮等。GO富集得出928条结果，其中生物过程808条，细胞组成41条，分子功能79条。KEGG通路富集得相关通路118条，提示鸡骨草作用于癌症信号通路、内分泌抗性、乙型肝炎信号通路、MAPK等多条信号通路。分子对接结果显示核心靶标和作用成分可以自由结合。结论 鸡骨草通过相思子碱、相思子皂醇、大豆甾醇等关键成分干预了ESR1、MMP9、STAT3及JUN等靶标，调节了乙型肝炎信号通路、缺氧诱导因子1信号通路及内分泌抗性等通路发挥治疗乙型肝炎作用。

Objective In this study, network pharmacology and molecular docking methods were used to reveal the mechanism of the treatment of hepatitis B by Abrus cantoniensis based on the association network of "medicinal material – component – target – pathway".Methods Screen the active components with OB≥30% and DL≤0.18 in Abrus cantoniensis based on the TCMSP, supplement the representative components of Abrus cantoniensis in the literature report, predict the target online through Swiss target prediction, and integrate the hepatitis B target in the GeneCards and DisGenet databases, Cytoscape screens the core target and performs GO and KEGG enrichment analysis, and uses molecular docking technology to verify the binding mode of the core target and the active component.Results There were 91 hepatitis B targets, including 17 core targets, including ESR1, MMP9, STAT3, JUN, and so on. The core ingredients include abrine, abrisapogenol, soyasapogenol, 2', 4'-dihydroxychalcone, etc. 928 results were obtained by GO enrichment, including 808 biological processes, 41 cell composition and 79 molecular functions. KEGG pathway was enriched in 118 related pathways, suggesting that Abrus cantoniensis acts on cancer signaling pathway, endocrine resistance pathway, hepatitis B signaling pathway, MAPK and other signaling pathways. Molecular docking results showed that the core target and the active component could freely combine.Conclusion Through key components such as abrine, abrisapogenol, soyasapogenol and other components interferes with ESR1, MMP9, STAT3 and JUN, and regulates hepatitis B signaling pathway, hypoxia-inducible factor 1 signaling pathway and endocrine resistance pathway to play a therapeutic role in hepatitis B.

R285.5

广西重点研发计划（桂科AB20159029）；广西科技计划项目（桂科AD18126013）；科技创新基地建设项目（桂科ZY21195044）